[{"AccountsPayableCurrent_0_Q2_USD":8766000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":592000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":9892000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":4072000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":2624000.0,"IntangibleAssetsNetExcludingGoodwill_0_Q2_USD":2134000.0,"OtherLiabilitiesCurrent_0_Q2_USD":168000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_Q2_USD":-20759000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q2_USD":-1108000.0,"IncreaseDecreaseInOtherOperatingAssets_2_Q2_USD":-615000.0,"IncreaseDecreaseInContractWithCustomerLiability_2_Q2_USD":49074000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_2_Q2_USD":39931000.0,"ForeignCurrencyTransactionGainLossBeforeTax_1_Q2_USD":-182000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":126683000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_Q2_USD":0.47,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1_Q2_USD":0.3,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_2_Q2_USD":0.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_1_Q2_USD":0.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":113000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":699000.0,"IncreaseDecreaseInAccountsPayableTrade_2_Q2_USD":3571000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":5075000.0,"InvestmentIncomeInterest_2_Q2_USD":1877000.0,"InvestmentIncomeInterest_1_Q2_USD":1147000.0,"IncomeTaxesReceivable_0_Q2_USD":26746000.0,"OtherAssetsCurrent_0_Q2_USD":2929000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-59588000.0,"ForeignCurrencyTransactionGainLossBeforeTax_2_Q2_USD":907000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q2_USD":296629000.0,"RestrictedCashAndCashEquivalentsNoncurrent_0_Q2_USD":4324000.0,"RecordedUnconditionalPurchaseObligation_0_Q2_USD":2500000.0,"PaymentsToAcquireMarketableSecurities_2_Q2_USD":298016000.0,"OtherOperatingActivitiesCashFlowStatement_2_Q2_USD":718000.0,"OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_2_Q2_USD":0.0,"OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_1_Q2_USD":0.0,"OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_2_Q2_USD":0.0,"OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_1_Q2_USD":0.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1_Q2_USD":1194000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2_Q2_USD":19105000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":18892000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":2624000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":20814000.0,"ForeignCurrencyTransactionGainLossUnrealized_2_Q2_USD":2004000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_Q2_USD":-678000.0,"DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_0_Q2_security":26.0,"DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0_Q2_USD":168200000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_0_Q2_security":0.0,"ContractWithCustomerLiabilityRevenueRecognized_2_Q2_USD":1200000.0,"ContractWithCustomerLiabilityRevenueRecognized_1_Q2_USD":400000.0,"ContractWithCustomerLiabilityNoncurrent_0_Q2_USD":44651000.0,"ContractWithCustomerLiabilityCurrent_0_Q2_USD":3464000.0,"ContractWithCustomerLiability_0_Q2_USD":48100000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":71775000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":2493000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-29095000.0,"PaymentsToAcquireIntangibleAssets_2_Q2_USD":407000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":2057000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-258952000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":339463000.0,"LiabilitiesCurrent_0_Q2_USD":38559000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":512201000.0,"Liabilities_0_Q2_USD":104616000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":95000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":25000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":-57952000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":-29855000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":19556000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":10295000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-8058000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-0.07,"Depreciation_2_Q2_USD":3583000.0,"CostsAndExpenses_2_Q2_USD":61280000.0,"CostsAndExpenses_1_Q2_USD":30755000.0,"CommonStockValue_0_Q2_USD":1324000.0,"CommonStockSharesOutstanding_0_Q2_shares":927668946.0,"CommonStockSharesIssued_0_Q2_shares":927668946.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":122359000.0,"AssetsCurrent_0_Q2_USD":458087000.0,"Assets_0_Q2_USD":512201000.0,"AdditionalPaidInCapital_0_Q2_USD":928777000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-8805000.0,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.04,"NetIncomeLoss_1_Q2_USD":-29880000.0,"NetIncomeLoss_2_Q2_USD":-58047000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":460000.0,"StockIssuedDuringPeriodValueNewIssues_1_Q2_USD":243838000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_Q2_shares":12968216.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1_Q2_shares":2738936.0,"PrepaidExpenseCurrent_0_Q2_USD":7903000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":188000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":-749000.0,"AmortizationOfIntangibleAssets_2_Q2_USD":464000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q2_USD":26100000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":4181000.0,"ShareBasedCompensation_2_Q2_USD":4072000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":41724000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":20460000.0,"OperatingIncomeLoss_2_Q2_USD":-60017000.0,"OperatingIncomeLoss_1_Q2_USD":-30253000.0,"CommonStockSharesAuthorized_0_Q2_shares":1038249630.0,"CommonStockParOrStatedValuePerShare_0_Q2_GBP":0.001,"AccruedLiabilitiesCurrent_0_Q2_USD":23836000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":781235457.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":822725556.0,"StockholdersEquity_0_Q2_USD":407585000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-513711000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":27020000.0,"ProfitLoss_2_Q2_USD":-58047000.0,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":334388000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":39099000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":502000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":1263000.0,"Ticker":"ADAP","CIK":"1621227","name":"ADAPTIMMUNE THERAPEUTICS PLC","OfficialName":"Adaptimmune Therapeutics plc American Depositary Shares","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"301181409.0","Country":"United Kingdom","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20200806"}]